©The Author(s) 2025.
World J Cardiol. Oct 26, 2025; 17(10): 111462
Published online Oct 26, 2025. doi: 10.4330/wjc.v17.i10.111462
Published online Oct 26, 2025. doi: 10.4330/wjc.v17.i10.111462
Figure 7 Therapeutic strategies in cardiomyopathy of endocrine origin.
GLP-1: Glucagon-like peptide-1; SGLT2: Sodium-glucose cotransporter-2.
- Citation: Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Morón-Siguas JC, Muñoz-Moreno JM, Pérez-Reyes AI, Martinez-Galaviz R, Aguilar-Castañeda RD, González-Godoy O, Concepción-Urteaga LA, Paz-Ibarra J. Cardiomyopathies of endocrine origin: A state-of-the-art review. World J Cardiol 2025; 17(10): 111462
- URL: https://www.wjgnet.com/1949-8462/full/v17/i10/111462.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i10.111462